Min Pan
Min Pan has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Chang Liu
Department of Hepatobiliary Surgery and Liver Transplantation, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publication - Fengping Zhang
Department of Hepatobiliary Surgery
1 shared publication - Jingyao Zhang
Department of Surgical Intensive Care Unit, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, People’s Republic of China
1 shared publication - Kai Qu
Department of Hepatobiliary Surgery and Liver Transplantation The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7805115
TXNIP: A Double‐Edged Sword in Disease and Therapeutic Outlook
Thioredoxin‐interacting protein (TXNIP) was originally named vitamin D3 upregulated protein‐1 (VDUP1) because of its ability to bind to thioredoxin (TRX) and inhibit TRX function and expression. TXNIP is an alpha‐arrestin protein that is essential for redox homeostasis in the human body. TXNIP may act as a double‐edged sword in the cell. The balance of TXNIP is crucial. A study has shown that TXNIP can travel between diverse intracellular locations and bind to different proteins to play different roles under oxidative stress. The primary function of TXNIP is to induce apoptosis or pyroptosis under oxidative stress. TXNIP also inhibits proliferation and migration in cancer cells, although TXNIP levels decrease, and function diminishes in various cancers. In this review, we summarized the main structure, binding proteins, pathways, and the role of TXNIP in diseases, aiming to explore the double‐edged sword role of TXNIP, and expect it to be helpful for future treatment using TXNIP as a therapeutic target.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7805115
Top Cited PapersOpen AccessTXNIP: A Double‐Edged Sword in Disease and Therapeutic Outlook
Thioredoxin‐interacting protein (TXNIP) was originally named vitamin D3 upregulated protein‐1 (VDUP1) because of its ability to bind to thioredoxin (TRX) and inhibit TRX function and expression. TXNIP is an alpha‐arrestin protein that is essential for redox homeostasis in the human body. TXNIP may act as a double‐edged sword in the cell. The balance of TXNIP is crucial. A study has shown that TXNIP can travel between diverse intracellular locations and bind to different proteins to play different roles under oxidative stress. The primary function of TXNIP is to induce apoptosis or pyroptosis under oxidative stress. TXNIP also inhibits proliferation and migration in cancer cells, although TXNIP levels decrease, and function diminishes in various cancers. In this review, we summarized the main structure, binding proteins, pathways, and the role of TXNIP in diseases, aiming to explore the double‐edged sword role of TXNIP, and expect it to be helpful for future treatment using TXNIP as a therapeutic target.